Northwest Biotherapeutics has expanded its senior management team with the addition of Dr. Kevin T. Duffy as vice president, Medical Affairs and External Collaborations.

Dr. Duffy joins the company from Merck, where he served as Research Scientific Director in the Keytruda program during the last five years.  Dr. Duffy’s roles included scientific support and outreach to health care providers and national and regional scientific leaders in over 20 different solid tumors and hematologic malignancies (blood cancers and lymphomas) relating to Merck’s clinical development and commercialization of Keytruda, as well as ongoing scientific support for Merck’s Investigator-Initiated Study Program. He served as the national contact point between the scientific affairs team in the field and the internal R&D team in Merck for studies in first-line non-small cell lung cancer, triple negative breast cancer and ER+/HER2- breast cancer, and metastatic prostate cancer.  

Prior to Merck, Dr. Duffy served in Medical Affairs and Scientific Affairs positions in several pharmaceutical companies, including as a Regional Scientific Manager for oncology and cardiovascular therapeutics at AstraZeneca.  Dr. Duffy has a Ph.D. in molecular pharmacology and structural biology, with a focus on oncology, as well as an MBA.  

Linda Powers, chief executive officer of NW Bio, said, “Dr. Duffy’s experience with immune therapies for cancer and one of the most successful product development programs in the field will be an invaluable addition to our team.  We at NW Bio could not be more excited about Dr. Duffy’s choice to join us and help realize the broad potential of DCVax.”